Different Mutagenic Potential of HIV-1 Restriction Factors APOBEC3G and APOBEC3F Is Determined by Distinct Single-Stranded DNA Scanning Mechanisms

PLoS Pathogens

Volumn 10, Issue 3, 2014, Pages

  Ara, Anjuman ^a   Love, Robin P ^a   Chelico, Linda ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTOSINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; SINGLE STRANDED DNA; URACIL;

ARTICLE; CHEMICAL ANALYSIS; CIRCULAR DICHROISM; DEAMINATION; ENZYME ANALYSIS; ENZYME SUBSTRATE; GEL PERMEATION CHROMATOGRAPHY; GENE INACTIVATION; GENE TRANSLOCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RESTRICTION MAPPING; VIRUS INFECTIVITY; VIRUS REPLICATION;

AMINO ACID MOTIFS; ANIMALS; ANISOTROPY; CELL LINE; CHROMATOGRAPHY, GEL; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; DNA, SINGLE-STRANDED; DNA, VIRAL; GENE SILENCING; HIV-1; HUMANS; IMMUNOBLOTTING; MUTAGENESIS;

EID: 84897405060     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004024     Document Type: Article

References (72)

1. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, et al. (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79: 285-296.
2. Harris RS, Hultquist JF, Evans DT, (2012) The restriction factors of human immunodeficiency virus. J Biol Chem 287: 40875-40883.
3. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, et al. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14: 1392-1396.
4. Zennou V, Bieniasz PD, (2006) Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 349: 31-40.
5. Liddament MT, Brown WL, Schumacher AJ, Harris RS, (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14: 1385-1391.
6. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR, (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 23: 2451-2458.
7. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, et al. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 78: 6073-6076.
8. Albin JS, Harris RS, (2010) Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 12: e4.
9. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
10. Conticello SG, Harris RS, Neuberger MS, (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13: 2009-2013.
11. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, et al. (2003) The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 77: 11398-11407.
12. Sheehy AM, Gaddis NC, Malim MH, (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
13. Stopak K, de Noronha C, Yonemoto W, Greene WC, (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12: 591-601.
14. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056-1060.
15. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
16. Navarro F, Bollman B, Chen H, Konig R, Yu Q, et al. (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology 333: 374-386.
17. Hache G, Liddament MT, Harris RS, (2005) The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem 280: 10920-10924.
18. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, et al. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11: 435-442.
19. Suspene R, Sommer P, Henry M, Ferris S, Guetard D, et al. (2004) APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res 32: 2421-2429.
20. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, et al. (2011) Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 85: 11220-11234.
21. Refsland EW, Hultquist JF, Harris RS, (2012) Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog 8: e1002800.
22. Mulder LC, Ooms M, Majdak S, Smedresman J, Linscheid C, et al. (2010) Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J Virol 84: 9613-9617.
23. Miyagi E, Brown CR, Opi S, Khan M, Goila-Gaur R, et al. (2010) Stably expressed APOBEC3F has negligible antiviral activity. J Virol 84: 11067-11075.
24. Chaipan C, Smith JL, Hu WS, Pathak VK, (2013) APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol 87: 444-453.
25. Koning FA, Goujon C, Bauby H, Malim MH, (2011) Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J Virol 85: 13448-13452.
26. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, et al. (2011) APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog 7: e1002221.
27. Wang T, Zhang W, Tian C, Liu B, Yu Y, et al. (2008) Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. Virology 377: 71-79.
28. Pak V, Heidecker G, Pathak VK, Derse D, (2011) The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B. J Virol 85: 8538-8547.
29. Gillick K, Pollpeter D, Phalora P, Kim EY, Wolinsky SM, et al. (2013) Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J Virol 87: 1508-1517.
30. Langlois MA, Beale RC, Conticello SG, Neuberger MS, (2005) Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res 33: 1913-1923.
31. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, et al. (2009) Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 83: 9474-9485.
32. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, et al. (2010) Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 38: 4274-4284.
33. Song C, Sutton L, Johnson ME, D'Aquila RT, Donahue JP, (2012) Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction. J Biol Chem 287: 16965-16974.
34. Feng Y, Chelico L, (2011) Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain. J Biol Chem 286: 11415-11426.
35. Chelico L, Pham P, Calabrese P, Goodman MF, (2006) APOBEC3G DNA deaminase acts processively 3′→5′ on single-stranded DNA. Nat Struct Mol Biol 13: 392-399.
36. Nowarski R, Britan-Rosich E, Shiloach T, Kotler M, (2008) Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat Struct Mol Biol 15: 1059-1066.
37. Shlyakhtenko LS, Lushnikov AY, Miyagi A, Li M, Harris RS, et al. (2012) Nanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA. Biochemistry 51: 6432-6440.
38. Berg OG, Winter RB, von Hippel PH, (1981) Diffusion-driven mechanisms of protein translocation on nucleic acids. 1. Models and theory. Biochemistry 20: 6929-6948.
39. Halford SE, Marko JF, (2004) How do site-specific DNA-binding proteins find their targets? Nucleic Acids Res 32: 3040-3052.
40. von Hippel PH, Berg OG, (1989) Facilitated target location in biological systems. J Biol Chem 264: 675-678.
41. Marklund EG, Mahmutovic A, Berg OG, Hammar P, van der Spoel D, et al. (2013) Transcription-factor binding and sliding on DNA studied using micro- and macroscopic models. Proc Natl Acad Sci U S A 110: 19796-19801.
42. Senavirathne G, Jaszczur M, Auerbach PA, Upton TG, Chelico L, et al. (2012) Single-stranded DNA scanning and deamination by APOBEC3G cytidine deaminase at single molecule resolution. J Biol Chem 287: 15826-15835.
43. Feng Y, Love RP, Chelico L, (2013) HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G. J Biol Chem 288: 6083-6094.
44. Love RP, Xu H, Chelico L, (2012) Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A. J Biol Chem 287: 30812-30822.
45. Browne EP, Allers C, Landau NR, (2009) Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 387: 313-321.
46. Creighton S, Bloom LB, Goodman MF, (1995) Gel fidelity assay measuring nucleotide misinsertion, exonucleolytic proofreading, and lesion bypass efficiencies. Methods Enzymol 262: 232-256.
47. Chelico L, Sacho EJ, Erie DA, Goodman MF, (2008) A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV. J Biol Chem 283: 13780-13791.
48. Chelico L, Pham P, Petruska J, Goodman MF, (2009) Biochemical basis of immunological and retroviral responses to DNA-targeted cytosine deamination by activation-induced cytidine deaminase and APOBEC3G. J Biol Chem 284: 27761-27765.
49. Shlyakhtenko LS, Lushnikov AY, Li M, Lackey L, Harris RS, et al. (2011) Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J Biol Chem 286: 3387-3395.
50. Shlyakhtenko LS, Lushnikov AY, Miyagi A, Li M, Harris RS, et al. (2013) Atomic force microscopy studies of APOBEC3G oligomerization and dynamics. J Struct Biol 2: 217-225.
51. Wang X, Dolan PT, Dang Y, Zheng YH, (2007) Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle. J Biol Chem 282: 1585-1594.
52. Bohn MF, Shandilya SM, Albin JS, Kouno T, Anderson BD, et al. (2013) Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure 21: 1042-1050.
53. Holden LG, Prochnow C, Chang YP, Bransteitter R, Chelico L, et al. (2008) Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456: 121-124.
54. Chelico L, Prochnow C, Erie DA, Chen XS, Goodman MF, (2010) Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J Biol Chem 285: 16195-16205.
55. Chen KM, Harjes E, Gross PJ, Fahmy A, Lu Y, et al. (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452: 116-119.
56. Lieberman BA, Nordeen SK, (1997) DNA intersegment transfer, how steroid receptors search for a target site. J Biol Chem 272: 1061-1068.
57. Furukawa A, Nagata T, Matsugami A, Habu Y, Sugiyama R, et al. (2009) Structure and real-time monitoring of the enzymatic reaction of APOBEC3G which is involved in anti-HIV activity. Nucleic Acids Symp Ser (Oxf) pp. 87-88.
58. Loeb DD, Swanstrom R, Everitt L, Manchester M, Stamper SE, et al. (1989) Complete mutagenesis of the HIV-1 protease. Nature 340: 397-400.
59. Suspene R, Rusniok C, Vartanian JP, Wain-Hobson S, (2006) Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 34: 4677-4684.
60. Mbisa JL, Bu W, Pathak VK, (2010) APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J Virol 84: 5250-5259.
61. Albin JS, Hache G, Hultquist JF, Brown WL, Harris RS, (2010) Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J Virol 84: 10209-10219.
62. Hache G, Shindo K, Albin JS, Harris RS, (2008) Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr Biol 18: 819-824.
63. Holmes RK, Koning FA, Bishop KN, Malim MH, (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282: 2587-2595.
64. Yang Y, Guo F, Cen S, Kleiman L, (2007) Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 365: 92-100.
65. Bransteitter R, Prochnow C, Chen XS, (2009) The current structural and functional understanding of APOBEC deaminases. Cell Mol Life Sci 66: 3137-3147.
66. Harjes E, Gross PJ, Chen KM, Lu Y, Shindo K, et al. (2009) An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J Mol Biol 389: 819-832.
67. Sadler HA, Stenglein MD, Harris RS, Mansky LM, (2010) APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol 84: 7396-7404.
68. Le Grice SF, Gruninger-Leitch F, (1990) Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur J Biochem 187: 307-314.
69. Gao F, Robertson DL, Morrison SG, Hui H, Craig S, et al. (1996) The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 70: 7013-7029.
70. Belanger K, Savoie M, Rosales Gerpe MC, Couture JF, Langlois MA, (2013) Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses. Nucleic Acids Res 41: 7438-7452.
71. O'Doherty U, Swiggard WJ, Malim MH, (2000) Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 74: 10074-10080.
72. Stanford NP, Szczelkun MD, Marko JF, Halford SE, (2000) One- and three-dimensional pathways for proteins to reach specific DNA sites. EMBO J 19: 6546-6557.